What is the maximum duration of use of somituximab (Mirvetuximab)?

Somituximab (Mirvetuximab) is an antibody drug conjugate (ADC), mainly used to treat patients with advanced platinum-resistant ovarian cancer , fallopian tube cancer, and peritoneal cancer, especially those FRα (folate receptor alpha)-positive patients. This medication is given as an intravenous drip, usually every three weeks. A patient's duration of treatment depends primarily on their tolerance of the drug and the benefit they receive from treatment.

The duration of treatment with somituximab is generally determined by patient response and tolerability. If a patient is benefiting from the drug and is not experiencing serious side effects, doctors usually recommend continuing treatment until the patient's condition changes significantly or unacceptable side effects develop. Typically, patients receiving somituximab receive infusions every three weeks and continue the drug until disease progression or intolerable side effects occur.

During treatment, doctors will closely monitor the patient's condition and any side effects caused by the medication. For example, somituximab may cause side effects such as fatigue, nausea, and hematological toxicity (eg, anemia, leukopenia). When these side effects occur, treatment may be adjusted, including reducing the dose of the drug or suspending treatment. In some cases, patients may need to stop treatment if side effects are severe. Usually, doctors will flexibly adjust the treatment plan according to the patient's specific situation to ensure the maximum therapeutic effect while minimizing side effects.

However, specific guidelines regarding the maximum duration of somituximab use are unclear. As with many cancer treatments, the duration of use of somituximab depends on a variety of factors, including the patient's condition, treatment response, and tolerability. For some patients, treatment with somituximab may continue for several months or even longer until disease progression or intolerable side effects occur. For other patients, treatment may be stopped early to prevent side effects from accumulating.

Reference materials:https://go.drugbank.com/drugs/DB12489